News Related to Neuroendocrine Prostate Cancer

Related coverage linked through entity extraction aliases.

Zocilurtatug pelitecan shows responses in pretreated extrapulmonary neuroendocrine carcinomas

Apr 26, 2026

Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.

Yale Cancer Center presents new findings at 2026 AACR Annual Meeting

Apr 24, 2026

Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.